Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Status:
Not yet recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants
with idiopathic pulmonary fibrosis (IPF). The dose level and interval for each IPF
participant cohort will be selected by the sponsor based on review of all available safety
and PD data.